A drug from the sea that strikes tumor-associated macrophages

Paola Allavena, Giovanni Germano, Cristina Belgiovine, Maurizio D'Incalci, Alberto Mantovani

Research output: Contribution to journalArticlepeer-review


Tumor-associated macrophages (TAMs) and other myeloid cells that infiltrate neoplastic lesions promote tumor progression and are associated with poor patient prognosis. We have recently demonstrated that trabectedin, a licensed and commercially available anticancer agent, is selectively cytotoxic for TAMs and their circulating precursors (monocytes). The macrophage-depleting effect of trabectedin is a key component of its antitumor activity.

Original languageEnglish
Article numbere24614
Issue number6
Publication statusPublished - Jun 2013


  • Angiogenesis
  • Chemotherapy
  • Marine drug
  • Micro-environment
  • Tumor-associated macrophages

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology


Dive into the research topics of 'A drug from the sea that strikes tumor-associated macrophages'. Together they form a unique fingerprint.

Cite this